Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Vicente Pernias‐Escrig"'
Autor:
José Miguel Rivera‐Caravaca, Juan Miguel Ruiz‐Nodar, Antonio Tello‐Montoliu, María Asunción Esteve‐Pastor, Miriam Quintana‐Giner, Andrea Véliz‐Martínez, Esteban Orenes‐Piñero, Ana Isabel Romero‐Aniorte, Nuria Vicente‐Ibarra, Vicente Pernias‐Escrig, Luna Carrillo‐Alemán, Elena Candela‐Sánchez, Ignacio Hortelano, Beatriz Villamía, Miriam Sandín‐Rollán, Laura Nuñez‐Martínez, Mariano Valdés, Francisco Marín
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 9 (2018)
BackgroundA simple method to assess renal function is the estimated glomerular filtration rate, and it shows prognostic implications. However, it remains unknown which equation should be used in patients with acute coronary syndrome. We compared the
Externí odkaz:
https://doaj.org/article/890f422fbfcf417889133a50973494cc
Autor:
Vicente Pernias Escrig, Gregorio de Lara Delgado, Laura Núñez Martínez, Paula Guedes Ramallo, Manuel Gómez Martínez, Pedro Morillas Blasco
Publikováno v:
Cirugía Cardiovascular, Vol 24, Iss 6, Pp 356-357 (2017)
Externí odkaz:
https://doaj.org/article/ba96a07a08234d0184802e09bf6caa83
Autor:
Luna Carrillo-Alemán, Juan Gabriel Martínez-Martínez, Nuria Vicente-Ibarra, María Asunción Esteve-Pastor, Miriam Sandín-Rollán, Francisco Marcos Marín, Manuel Macías, Juan M. Ruiz-Nodar, Esteban Orenes-Piñero, Teresa Lozano, José Miguel Rivera-Caravaca, Vicente Pernias-Escrig, Elena Candela-Sánchez, Andrea Veliz, Miriam Quintana-Giner
Publikováno v:
Clinical Drug Investigation. 39:275-283
Dual antiplatelet therapy is one of the main treatments in acute coronary syndrome (ACS). Switching antiplatelet agents may be necessary in some patients to improve efficacy or safety. The objective of this study was to determine the prevalence, pred
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46aef030890e0064206f042e89f1d06
https://doi.org/10.1007/s40261-018-0736-z
https://doi.org/10.1007/s40261-018-0736-z
Autor:
Eduardo Núñez, Juan Sanchis Forés, Francisco Marín, Gonzalo Luis Alonso Salinas, Francesc Formiga Pérez, Emad Abu Assi, Albert Ariza Solé, Vicente Pernias Escrig, Pedro Rigueiro Veloso, Juan M. Ruiz-Nodar, Manuel Martínez-Sellés, Alberto Cordero Fort, José María García Acuña, Alfredo Bardají Ruiz, P. Díez Villanueva, José A. Barrabés, Sergio Raposeiras Roubín, Julio Núñez Villota, Nuria Vicente Ibarra
Publikováno v:
REC: interventional cardiology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3bc93dbf4b23bd11c6dc06b6f0c5f26
https://doi.org/10.24875/recic.m20000165
https://doi.org/10.24875/recic.m20000165
Autor:
Antonio Tello-Montoliu, Nuria Vicente-Ibarra, Juan M. Ruiz-Nodar, Teresa Lozano, María Asunción Esteve-Pastor, Manuel J Macías-Villanego, Francisco Marín, Vicente Pernias-Escrig, Luna Carrillo-Alemán, Juan Gabriel Martínez-Martínez, Esteban Orenes-Piñero, José Miguel Rivera-Caravaca, A Veliz-Martinez
Publikováno v:
The Journal of Clinical Pharmacology. 59:295-302
Chronic kidney disease (CKD) is associated with worse clinical outcomes in patients with acute coronary syndrome. However, they are underrepresented in clinical trials. We aimed to investigate differences in prognosis of acute coronary syndrome patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::966a5b61e2e527104b8855c26e027c8b
https://doi.org/10.1002/jcph.1318
https://doi.org/10.1002/jcph.1318
Autor:
Nuria Vicente-Ibarra, Francisco Marín, Vicente Pernias-Escrig, María Asunción Esteve-Pastor, Luna Carrillo Alemán, Manuel J Macías-Villanego, Elena Candela Sánchez, Miriam Sandín Rollán, José Miguel Rivera-Caravaca, Esteban Orenes-Piñero, Miriam Quintana-Giner, Antonio Tello-Montoliu, Juan M. Ruiz-Nodar, Teresa Lozano, A Veliz-Martinez, Mariano Valdés
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 23:57-65
Background: Current clinical guidelines of acute coronary syndromes (ACS) recommend the use of potent antiplatelet therapy, prasugrel or ticagrelor, because both drugs consistently reduce cardiovascular events. Purpose: The aim of this study was to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998ceab99567c94fd1db4becd6b8d4ec
https://doi.org/10.1177/1074248417724869
https://doi.org/10.1177/1074248417724869
Autor:
Vicente Pernias-Escrig, Mariano Valdés, Nuria Vicente-Ibarra, A Veliz-Martinez, María Asunción Esteve-Pastor, Luna Carrillo-Alemán, Francisco Marín, Miriam Sandín-Rollán, Antonio Tello-Montoliu, Elena Candela-Sánchez, Teresa Lozano, José Miguel Rivera-Caravaca, Manuel J Macías-Villanego, Juan M. Ruiz-Nodar, Esteban Orenes-Piñero
Publikováno v:
European Journal of Cardiovascular Nursing. 16:696-703
Background: Being overweight increases the risk of cardiovascular diseases and mortality. However, among high-body-weight patients with established acute coronary syndrome (ACS) this evidence is not clear. In this scenario, a low body weight (LBW) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b032fc4385deebffae8a4e1c1e86dca5
https://doi.org/10.1177/1474515117710155
https://doi.org/10.1177/1474515117710155
Autor:
A Veliz-Martinez, J G Martinez-Martinez, Francisco Marcos Marín, Nuria Vicente-Ibarra, Antonio Tello-Montoliu, M A Esteve Pastor, Juan M. Ruiz-Nodar, Teresa Lozano, Esteban Orenes-Piñero, M Sandin Rollan, Manuel J Macías-Villanego, José Miguel Rivera-Caravaca, Vicente Pernias-Escrig, L Carrillo-Aleman, E Candela
Publikováno v:
European Heart Journal. 40
Background Prasugrel and Ticagrelor have demonstrated higher efficacy than clopidogrel in their main clinical trials for patients with Acute Coronary Syndrome (ACS). However, the long-term prognosis and different clinical characteristics related with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b23aea464204e74895f93e36fba589a
https://doi.org/10.1093/eurheartj/ehz745.0683
https://doi.org/10.1093/eurheartj/ehz745.0683
Autor:
M Sandin Rollan, M A Esteve Pastor, Manuel J Macías-Villanego, José Miguel Rivera-Caravaca, Miriam Quintana-Giner, Francisco Marcos Marín, Antonio Tello-Montoliu, Teresa Lozano, Nuria Vicente-Ibarra, E Candela, Juan M. Ruiz-Nodar, Esteban Orenes-Piñero, Vicente Pernias-Escrig, L Carrillo-Aleman, A Veliz-Martinez
Publikováno v:
European Heart Journal. 40
Background Patients with acute coronary syndrome (ACS) and previous cardiovascular disease (CVD) [stroke, peripheral arterial disease (PAD) or coronary artery disease (CAD)] are at high risk of serious events and mortality. Current clinical guideline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1faad5bbb6089f0b57548b9ea849fc45
https://doi.org/10.1093/eurheartj/ehz747.0533
https://doi.org/10.1093/eurheartj/ehz747.0533
Autor:
M Sandin Rollan, Manuel J Macías-Villanego, M A Esteve Pastor, L Nunez-Martinez, Teresa Lozano, Francisco Marcos Marín, Nuria Vicente-Ibarra, Antonio Tello-Montoliu, Juan M. Ruiz-Nodar, José Miguel Rivera-Caravaca, E Candela, A Veliz-Martinez, Esteban Orenes-Piñero, L Carrillo-Aleman, Vicente Pernias-Escrig
Publikováno v:
European Heart Journal. 40
Background Diabetic patients (DM) with an acute coronary syndrome (ACS) have a worse prognosis than non-diabetic patients. The new P2Y12 inhibitors, both ticagrelor and prasugrel, have shown efficacy in cardiovascular event reduction in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83ad0f05d2a817e14f978424bf407d98
https://doi.org/10.1093/eurheartj/ehz745.0681
https://doi.org/10.1093/eurheartj/ehz745.0681